GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (NAS:PLUR) » Definitions » Cyclically Adjusted Price-to-FCF

Pluri (PLUR) Cyclically Adjusted Price-to-FCF : (As of May. 05, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Pluri Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pluri Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Pluri's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pluri Cyclically Adjusted Price-to-FCF Chart

Pluri Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pluri Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pluri's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Pluri's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pluri's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pluri's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pluri's Cyclically Adjusted Price-to-FCF falls into.



Pluri Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Pluri's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Pluri's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.726/129.4194*129.4194
=-0.726

Current CPI (Dec. 2023) = 129.4194.

Pluri Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -7.226 99.695 -9.381
201406 -6.485 100.560 -8.346
201409 -4.314 100.428 -5.559
201412 -6.679 99.070 -8.725
201503 -7.529 99.621 -9.781
201506 -5.847 100.684 -7.516
201509 -4.953 100.392 -6.385
201512 -4.018 99.792 -5.211
201603 -5.659 100.470 -7.290
201606 -5.748 101.688 -7.316
201609 -4.036 101.861 -5.128
201612 -5.828 101.863 -7.405
201703 -4.890 102.862 -6.153
201706 -5.340 103.349 -6.687
201709 -4.386 104.136 -5.451
201712 -3.702 104.011 -4.606
201803 -4.077 105.290 -5.011
201806 -4.251 106.317 -5.175
201809 -6.113 106.507 -7.428
201812 -5.721 105.998 -6.985
201903 -4.117 107.251 -4.968
201906 -3.650 108.070 -4.371
201909 -3.788 108.329 -4.525
201912 -3.202 108.420 -3.822
202003 -2.933 108.902 -3.486
202006 -2.175 108.767 -2.588
202009 -1.948 109.815 -2.296
202012 -2.485 109.897 -2.926
202103 -2.013 111.754 -2.331
202106 -2.437 114.631 -2.751
202109 -2.201 115.734 -2.461
202112 -2.463 117.630 -2.710
202203 -2.345 121.301 -2.502
202206 -2.131 125.017 -2.206
202209 -1.887 125.227 -1.950
202212 -1.530 125.222 -1.581
202303 -1.221 127.348 -1.241
202306 -0.585 128.729 -0.588
202309 -1.154 129.860 -1.150
202312 -0.726 129.419 -0.726

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pluri  (NAS:PLUR) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Pluri Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Pluri's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pluri (PLUR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (NAS:PLUR) » Definitions » Cyclically Adjusted Price-to-FCF
Traded in Other Exchanges
Address
MATAM Advanced Technology Park, Building No.5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.
Executives
Lorne Kenneth Abony director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Zami Aberman officer: Chief Executive Officer 63 RABUTZKY STREET, RAANANA L3 43220
Varda Shalev director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Pinhas Doron Birger director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Clover Wolf Capital - Limited Partnership 10 percent owner BOODENHIMER 24, TEL AVIV L3 6200838
Rami Avraham Levi director MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Maital Shemesh-rasmussen director MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Doron Shorrer director 33 KOREH PLADORR ST, JERUSALEM L3 93393
Isaac Braun director 9 ZEHARIA STREET, BENE BARAK L3 51540
Yaky Yanay officer: Chief Financial Officer ARGAMAN 14, SHIMSHIT L3 17906
Moria Kwiat director HAKFAR 11, KIRYAT ONO L3 55525
Israel Ben-yoram director 24 BARKAN STREET, RISHON LEZION L3 00000
Chen Franco-yehuda officer: Chief Financial Officer MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 31905
Mark Germain director WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Erez Egozi officer: Chief Financial Officer MATAM PARK, BUILDING 05, HAIFA L3 31905